Deal Making

Featured on Deal Making

Regeneron forks out $250m to buy Checkmate Pharmaceuticals
Deal-Making
Regeneron forks out $250m to buy Checkmate PharmaceuticalsRegeneron forks out $250m to buy Checkmate Pharmaceuticals

Regeneron will increase its research efforts in immuno-oncology through the all-cash acquisition of Checkmate Pharmaceuticals.

byMillie Nelson, Editor
Apr 25, 2022
|
2 Min Read
Ilya aims to strengthen supply chain with Nordic Bioanalysis buy
Deal-Making
Ilya aims to strengthen supply chain with Nordic Bioanalysis buyIlya aims to strengthen supply chain with Nordic Bioanalysis buy
byMillie Nelson
Apr 21, 2022
2 Min Read
Asahi Kasei enters CDMO biz with Bionova buy
Deal-Making
Asahi Kasei enters CDMO biz with Bionova buyAsahi Kasei enters CDMO biz with Bionova buy
byMillie Nelson
Apr 20, 2022
2 Min Read
Advanced therapy CDMO roundup: Deals for WuXi, Resilience, Fujifilm
Deal-Making
Advanced therapy CDMO roundup: Deals for WuXi, Resilience, FujifilmAdvanced therapy CDMO roundup: Deals for WuXi, Resilience, Fujifilm
byDan Stanton
Apr 14, 2022
2 Min Read
Vetter and Rentschler double down on CDMO collaboration
Bioprocess Insider
Vetter and Rentschler double down on CDMO collaborationVetter and Rentschler double down on CDMO collaboration
byDan Stanton
Mar 31, 2022
1 Min Read
Shape Therapeutics: ‘We’ve engineered a new kind of RNA’
Deal-Making
Shape Therapeutics: ‘We’ve engineered a new kind of RNA’Shape Therapeutics: ‘We’ve engineered a new kind of RNA’
byMillie Nelson
Mar 24, 2022
2 Min Read

More from Deal Making

Ginkgo adds cell programming platform with FGen buy
Deal-Making
Ginkgo adds cell programming platform with FGen buy
Ginkgo adds cell programming platform with FGen buy
Mar 21, 2022
|
2 Min Read
byMillie Nelson, Editor
Sanofi refills ADC pipeline with Seagen pact
Deal-Making
Sanofi refills ADC pipeline with Seagen pact
Sanofi refills ADC pipeline with Seagen pact
Mar 16, 2022
|
2 Min Read
byDan Stanton, Editorial director
Novartis playing in cell therapy CDMO space with Carisma
Deal-Making
Novartis playing in cell therapy CDMO space with Carisma
Novartis playing in cell therapy CDMO space with Carisma
Mar 14, 2022
|
2 Min Read
byDan Stanton, Editorial director
IDT Biologika and Exothera team on viral vaccine manufacturing
Deal-Making
IDT Biologika and Exothera team on viral vaccine manufacturing
IDT Biologika and Exothera team on viral vaccine manufacturing
Mar 8, 2022
|
2 Min Read
byMillie Nelson, Editor
Biovian to make AAVs for ANLBIO Alzheimer’s gene therapy candidate
Bioprocess Insider
Biovian to make AAVs for ANLBIO Alzheimer’s gene therapy candidate
Biovian to make AAVs for ANLBIO Alzheimer’s gene therapy candidate
Mar 7, 2022
|
2 Min Read
byDan Stanton, Editorial director
Emergent lowers CDMO guidance as J&J assesses COVID vaccine demand
Deal-Making
Emergent lowers CDMO guidance as J&J assesses COVID vaccine demand
Emergent lowers CDMO guidance as J&J assesses COVID vaccine demand
Mar 3, 2022
|
2 Min Read
byDan Stanton, Editorial director
Maravai LifeSciences: $11bn+ would deliver Sartorius a nucleic acid unit
Upstream & Downstream Processing
Maravai LifeSciences: $11bn+ would deliver Sartorius a nucleic acid unit
Maravai LifeSciences: $11bn+ would deliver Sartorius a nucleic acid unit
Mar 1, 2022
|
2 Min Read
byDan Stanton, Editorial director
Biocon buying Viatris biosimilar biz in $3.3bn deal
Deal-Making
Biocon buying Viatris biosimilar biz in $3.3bn deal
Biocon buying Viatris biosimilar biz in $3.3bn deal
Feb 28, 2022
|
2 Min Read
byDan Stanton, Editorial director
PerkinElmer teams with CRG for diabetes gene therapy
Deal-Making
PerkinElmer teams with CRG for diabetes gene therapy
PerkinElmer teams with CRG for diabetes gene therapy
Feb 28, 2022
|
1 Min Read
byMillie Nelson, Editor
Polyplus adds DNA services with e-Zyvec buy
Deal-Making
Polyplus adds DNA services with e-Zyvec buy
Polyplus adds DNA services with e-Zyvec buy
Feb 28, 2022
|
1 Min Read
byMillie Nelson, Editor
Takeda and Code Bio team up to make gene therapies logo in a gray background | Takeda and Code Bio team up to make gene therapies
Deal-Making
Takeda and Code Bio team up to make gene therapies
Takeda and Code Bio team up to make gene therapies
Feb 24, 2022
|
2 Min Read
byMillie Nelson, Editor
Catalent’s incoming CEO ready to stand on the shoulders of giants
Deal-Making
Catalent’s incoming CEO ready to stand on the shoulders of giants
Catalent’s incoming CEO ready to stand on the shoulders of giants
Feb 24, 2022
|
7 Min Read
byMillie Nelson, Editor
Recipharm bolsters biologics biz with Vibalogics buy
Deal-Making
Recipharm bolsters biologics biz with Vibalogics buy
Recipharm bolsters biologics biz with Vibalogics buy
Feb 21, 2022
|
1 Min Read
byMillie Nelson, Editor
Immunity pays $40 million to take on Athenex manufacturing plant
Deal-Making
Immunity pays $40 million to take on Athenex manufacturing plant
Immunity pays $40 million to take on Athenex manufacturing plant
Feb 21, 2022
|
2 Min Read
byGareth Macdonald
eTheRNA inks mRNA partnership with Merck KGaA
Deal-Making
eTheRNA inks mRNA partnership with Merck KGaA
eTheRNA inks mRNA partnership with Merck KGaA
Feb 17, 2022
|
2 Min Read
byMillie Nelson, Editor
Takeda contracts Resilience to bolster plasma network
Deal-Making
Takeda contracts Resilience to bolster plasma network
Takeda contracts Resilience to bolster plasma network
Feb 17, 2022
|
2 Min Read
byDan Stanton, Editorial director
UK reportedly selling £200m vaccine plant that never produced a single dose
Facilities & Capacity
UK reportedly selling £200m vaccine plant that never produced a single dose
UK reportedly selling £200m vaccine plant that never produced a single dose
Feb 14, 2022
|
2 Min Read
byDan Stanton, Editorial director
US Gov awards $250m botulinum contract to Resilience
Deal-Making
US Gov awards $250m botulinum contract to Resilience
US Gov awards $250m botulinum contract to Resilience
Feb 14, 2022
|
1 Min Read
byMillie Nelson, Editor
Intellia expands gene editing toolkit with $45m Rewrite buy
Deal-Making
Intellia expands gene editing toolkit with $45m Rewrite buy
Intellia expands gene editing toolkit with $45m Rewrite buy
Feb 7, 2022
|
1 Min Read
byMillie Nelson, Editor
Recipharm takes first step in DS biologics with GenIbet buy
Deal-Making
Recipharm takes first step in DS biologics with GenIbet buy
Recipharm takes first step in DS biologics with GenIbet buy
Feb 3, 2022
|
2 Min Read
byMillie Nelson, Editor
Univercells and RoosterBio target regen med commercialization
Deal-Making
Univercells and RoosterBio target regen med commercialization
Univercells and RoosterBio target regen med commercialization
Feb 1, 2022
|
2 Min Read
byMillie Nelson, Editor
Oxford Biomedica enters US through $180m Homology JV
Deal-Making
Oxford Biomedica enters US through $180m Homology JV
Oxford Biomedica enters US through $180m Homology JV
Jan 31, 2022
|
2 Min Read
byDan Stanton, Editorial director
Biogen pulling out of Bioepis JV in $2.3bn Samsung Bio deal
Deal-Making
Biogen pulling out of Bioepis JV in $2.3bn Samsung Bio deal
Biogen pulling out of Bioepis JV in $2.3bn Samsung Bio deal
Jan 31, 2022
|
2 Min Read
byDan Stanton, Editorial director
Fujifilm Dio signs long term supply deal and buys plant from Atara
Deal-Making
Fujifilm Dio signs long term supply deal and buys plant from Atara
Fujifilm Dio signs long term supply deal and buys plant from Atara
Jan 27, 2022
|
2 Min Read
byGareth Macdonald
Cytiva and Nucleus team on custom cell media for CGTs
Deal-Making
Cytiva and Nucleus team on custom cell media for CGTs
Cytiva and Nucleus team on custom cell media for CGTs
Jan 21, 2022
|
2 Min Read
byMillie Nelson, Editor
HPNE to expand single-use capacity on back of $15m BARDA contract
Upstream & Downstream Processing
HPNE to expand single-use capacity on back of $15m BARDA contract
HPNE to expand single-use capacity on back of $15m BARDA contract
Jan 20, 2022
|
2 Min Read
byDan Stanton, Editorial director
Novo Nordisk Foundation invests $343m to build stem-cell research center
Deal-Making
Novo Nordisk Foundation invests $343m to build stem-cell research center
Novo Nordisk Foundation invests $343m to build stem-cell research center
Jan 20, 2022
|
2 Min Read
byMillie Nelson, Editor
CBM and UPenn enter gene therapy manufacturing pact
Deal-Making
CBM and UPenn enter gene therapy manufacturing pact
CBM and UPenn enter gene therapy manufacturing pact
Jan 20, 2022
|
2 Min Read
byDan Stanton, Editorial director
BioNTech and Crescendo partner to develop precision immunotherapies
Deal-Making
BioNTech and Crescendo partner to develop precision immunotherapies
BioNTech and Crescendo partner to develop precision immunotherapies
Jan 19, 2022
|
1 Min Read
byMillie Nelson, Editor
TTP and CellFiber partner to ‘revolutionize’ CGTs
Deal-Making
TTP and CellFiber partner to ‘revolutionize’ CGTs
TTP and CellFiber partner to ‘revolutionize’ CGTs
Jan 18, 2022
|
2 Min Read
byMillie Nelson, Editor

Webinars

Ask the Expert webcasts
ATE Webcasts
Register Now: Big Impact from Small Samples: Harnessing High-Precision Tunable Laser Spectroscopy for Complex Bioprocessing Analysis
Register Now: Big Impact from Small Samples: Harnessing High-Precision Tunable Laser Spectroscopy for Complex Bioprocessing Analysis
Ask the Expert webcasts
ATE Webcasts
Register Now: Advancing mRNA and CircRNA-based Vaccines and Therapeutics in CMC: From Process Development to Analytics
Register Now: Advancing mRNA and CircRNA-based Vaccines and Therapeutics in CMC: From Process Development to Analytics
Insider News
See all
Jun 5 - Jun 6, 2024
Exploit Advances in Exosomes to Improve Efficiencies in Drug Delivery: Connect with senior-level executives and scientists who will share new data and novel case studies on advancing EV products through clinical stage towards commercialization
Learn More

Innovative Technology

Nagase Trehalose SG
Sponsored Content
Innovative Impurity Reduction in Harvesting Process With TREHALOSE SG
Innovative Impurity Reduction in Harvesting Process With TREHALOSE SG

Jan 9, 2025

Bruker Tornado Spectroscopy
Sponsored Content
Monitoring and Controlling Upstream Bioprocesses with Raman Spectroscopy
Monitoring and Controlling Upstream Bioprocesses with Raman Spectroscopy

Dec 1, 2024

Thermo Fisher White Paper
Sponsored Content
Peptones: A Powerful Tool for Manufacturing Complex Protein Therapies
Peptones: A Powerful Tool for Manufacturing Complex Protein Therapies

Nov 21, 2024

Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.
Subscribe